FDA halts tests of BioMarin drug amid heightened focus on gene therapy safety

The Food and Drug Administration has suspended testing of an experimental BioMarin Pharmaceutical gene therapy for the rare inherited disease phenylketonuria due to safety concerns reported in preclinical testing.